葛兰重金出手 9月23日，中欧基金发布关于旗下部分基金投资百利天恒非公开发行股票的公告，根据公告，葛兰 管理的中欧医疗健康混合基金认购百利天恒185.59万股，共计5.88亿元，占该基金资产净值比例 为1.8%。 牛市来了还没上车？上天天基金APP搜索777注册即可领500元券包，优选基金10元起投！限 量发放！先到先得！ 在近期的医药板块调整行情中，葛兰出手了！ 根据中欧基金公告，葛兰所管的两只基金豪掷6.79亿元，参与了创新药龙头公司百利天恒的增发。 此外，富国基金副总经理朱少醒、知名基金经理范妍等所管基金也参与了该公司的增发。从资金层 面看，在近期创新药板块的调整行情中，大量资金借道创新药主题ETF积极入市。 葛兰管理的另一只基金中欧医疗创新股票基金也认购百利天恒28.55万股，共计9050.98万元，占 该基金资产净值比例为1%。上述基金持股锁定期均为6个月。 根据基金定期报告，过去一年多来，葛兰一直在加仓百利天恒。 2024年底，中欧医疗健康混合基金持有百利天恒187.94万股，今年一季度大手笔加仓214.17万 股，二季度继续增持25.86万股，持股数量增至427.97万股。 截至今年二季度末，百 ...

在近期的医药板块调整行情中，葛兰出手了！ 根据中欧基金公告，葛兰所管的两只基金豪掷6.79亿元，参与了创新药龙头公司百利天恒的增发。此外，富国基金副总经理朱少醒、知名基金经理范妍等 所管基金也参与了该公司的增发。从资金层面看，在近期创新药板块的调整行情中，大量资金借道创新药主题ETF积极入市。 葛兰重金出手 9月23日，中欧基金发布关于旗下部分基金投资百利天恒非公开发行股票的公告，根据公告，葛兰管理的中欧医疗健康混合基金认购百利天恒185.59万 股，共计5.88亿元，占该基金资产净值比例为1.8%。 葛兰管理的另一只基金中欧医疗创新股票基金也认购百利天恒28.55万股，共计9050.98万元，占该基金资产净值比例为1%。上述基金持股锁定期均为6个 月。 | | 序号 品种代码 ⇒ | | 品种简称 | 持仓市值(元) ◆ | 占股票市值比 | 占基金净值比 | | --- | --- | --- | --- | --- | --- | --- | | | | | | | (%) = | (%) = | | 1 | 603259.SH | 药明康德 | 46,029,135.00 | 3,201,326,33 ...

根据中欧基金公告，葛兰所管的两只基金豪掷6.79亿元，参与了创新药龙头公司百利天恒的增发。此外，富国基金副总经理朱少醒、知名基金经理范妍等 所管基金也参与了该公司的增发。从资金层面看，在近期创新药板块的调整行情中，大量资金借道创新药主题ETF积极入市。 葛兰重金出手 9月23日，中欧基金发布关于旗下部分基金投资百利天恒非公开发行股票的公告，根据公告，葛兰管理的中欧医疗健康混合基金认购百利天恒185.59万 股，共计5.88亿元，占该基金资产净值比例为1.8%。 葛兰管理的另一只基金中欧医疗创新股票基金也认购百利天恒28.55万股，共计9050.98万元，占该基金资产净值比例为1%。上述基金持股锁定期均为6个 月。 在近期的医药板块调整行情中，葛兰出手了！ | 基金名称 | 认购数量 (股) | 总成本(元) | 总成本 占基金 | 账面价值(元) | 账面价 值占基 金资产 | 锁定 | | --- | --- | --- | --- | --- | --- | --- | | | | | 资产净 | | | 期 | | | | | 值比例 | | 浄值比 | | | | | | | | 例 (%) | | ...

Core Viewpoint - Baili Tianheng successfully raised a total of 3.764 billion yuan through a private placement of A-shares, which will accelerate the development of its innovative drug pipeline and help the company enter the ranks of entry-level multinational corporations (MNCs) [1][4] Fundraising Details - The private placement attracted participation from 18 well-known domestic and international institutions, with a share price of 317 yuan, significantly above the base price of 266.02 yuan [1][2] - The issuance was highly anticipated in the market, with 30 investors submitting bids, and the final price set at 317 yuan per share, reflecting strong confidence in the company's R&D capabilities and growth prospects [1][4] Use of Proceeds - The raised funds will be fully allocated to innovative drug research and development projects, particularly focusing on the HIRE-ADC platform and GNC platform for innovative antibody drugs [2][3] - The ADC drug development platform will advance clinical trials for six ADC drugs, targeting over ten indications, including lung cancer and breast cancer [3] Clinical Development Plans - The company is conducting over 40 clinical trials for the BL-B01D1/iza-bren drug in China and the U.S., with several indications included in breakthrough therapy designations by the FDA and CDE [3] - The GNC platform will accelerate the clinical development of multi-specific antibodies, further enriching the company's innovative drug pipeline [3] Strategic Importance - This fundraising is a key initiative in the company's "Quality Improvement, Efficiency Enhancement, and Return to Action Plan" for 2025, with a significant increase in R&D investment [4] - The successful implementation of this private placement not only reflects market recognition of the value of innovative pharmaceutical companies but also marks the company's strategic commitment to becoming a global MNC under the guidance of the "Eight Policies" [4]